Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2021-04-12 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
上海荣正投资咨询股份有限公司关于公司2019年限制性股票激励计划首次授予部分第二个解除限售期和预留授予部分第一个解除限售期解除限售相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2019 Restricted Stock Incentive Plan of Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. It discusses the approval, authorization, and conditions for lifting restrictions on stock incentives, including detailed financial and performance conditions, audit confirmations, and compliance with relevant laws and regulations. The document is not a general annual report or earnings release but a specialized advisory report on stock incentive plan matters. It contains substantive financial and compliance analysis related to the stock incentive plan and its unlocking conditions. This fits the definition of an Audit Report / Information (AR), as it is a standalone report providing audit-related opinions and financial advisory on a specific corporate action, not a full annual report or other category. The document length and content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2020
2021-04-12 Chinese
上海市锦天城律师事务所关于公司2019年限制性股票激励计划第一个解除限售期解除限售及回购注销部分限制性股票相关事项的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2019 restricted stock incentive plan of Xiamen Aide Biomedical Technology Co., Ltd. It discusses the approval, authorization, conditions for lifting restrictions on stock, repurchase and cancellation of restricted stock, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion. It is a legal opinion related to stock incentive plan implementation and compliance, which does not fit into categories like Annual Report, Interim Report, or Capital Update. It is also not a simple announcement or voting result. The document is a standalone legal opinion report on stock incentive plan matters, which aligns best with Audit Report / Information (AR) as it involves legal and compliance verification related to stock incentives and corporate governance matters. Confidence is high given the detailed legal analysis and formal opinion format. FY 2020
2021-04-12 Chinese
关于2019年限制性股票激励计划首次授予部分第二个限售期解除限售条件成就的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the unlocking of restricted shares under a 2019 restricted stock incentive plan by Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. It includes information about the approval procedures, performance conditions, number of shares unlocked, opinions from the board, independent directors, supervisory board, legal counsel, and independent financial advisors. The document is not a full financial report, earnings release, or management discussion, but rather a formal announcement about the status of a stock incentive plan and the unlocking of shares. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is also not a proxy solicitation or voting results announcement. The content is about share unlocking under an incentive plan, which is a capital/financing related update. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length is over 6000 characters, so it is not a mere announcement of a report publication (RPA).
2021-04-12 Chinese
中信证券关于公司2020年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2020 annual special audit of the fundraising funds' deposit and usage by Xiamen Aide Biomedical Technology Co., Ltd. It includes specific financial figures, regulatory references, audit opinions, and detailed tables about the use and management of the raised funds. The document references regulatory guidelines and includes an auditor's verification report. It is not a general annual report or earnings release but a specialized audit report focused on the use of raised capital. The presence of an auditor's opinion and detailed fund usage aligns with the definition of an Audit Report / Information (AR). The document length and content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-04-12 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and an "内部控制自我评价报告" (Internal Control Self-Evaluation Report) for the fiscal year ending December 31, 2020. It includes detailed descriptions of the company's internal control environment, control activities, evaluation criteria, and conclusions on the effectiveness of internal controls related to financial reporting and non-financial reporting. The document is issued by a registered accounting firm and the company's board, indicating it is a standalone audit-related assurance report on internal controls rather than a full annual report or interim financial report. It does not contain comprehensive financial statements or earnings highlights but focuses on internal control evaluation and assurance. This matches the definition of an Audit Report / Information (AR) which includes standalone audit reports and internal control assessments. The document length (14,600 characters) and detailed content confirm it is the report itself, not just an announcement or certification letter. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-04-12 Chinese
独立董事述职报告（蔡宁）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2020 Annual Report" from Xiamen Aide Biomedical Technology Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various company matters, committee work, on-site inspections, investor protection efforts, training, and other work during the 2020 fiscal year. The content is a detailed report of the independent director's duties and responsibilities over the year, rather than a general annual report or financial statement. It is not a certification, call transcript, or announcement. The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement. This type of document fits best under the category of Board/Management Information (MANG), as it relates to the independent director's report on their role and activities within the company's governance structure.
2021-04-12 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.